Plan targets companies outside pricing deals
President Donald Trump is preparing to impose sweeping new tariffs on pharmaceutical imports, targeting companies that have not agreed to sell medications directly to consumers under his “Most Favored Nation” pricing initiative.
According to a draft executive order reviewed by media outlets, patented drugs and their active pharmaceutical ingredients could face a 100% tariff. The proposal is not yet finalized and may change, but the administration is reportedly considering announcing the measures as early as Thursday.
Incentives to negotiate or relocate production
The draft outlines potential pathways for drugmakers to reduce or avoid the steep levies. Companies that join the administration’s pricing initiative would be exempt from the 100% tariff.
Additionally, firms that commit to relocating drug manufacturing to the United States could see their tariff rate lowered to 20% for four years. However, under the proposal, that reduced rate would revert to 100% beginning in 2030.
It remains unclear whether certain categories of medicines would be excluded or whether additional adjustments will be made before the order is finalized.
Part of broader trade strategy reset
The proposed drug tariffs represent an early move in Trump’s effort to reshape his trade policy following a February Supreme Court ruling that invalidated portions of his earlier tariff program. The court determined that some of the prior levies exceeded executive authority.
Trump has criticized the ruling and signaled that his administration will pursue alternative regulatory mechanisms to reintroduce broad tariffs. The pharmaceutical sector now appears to be a central focus of that strategy.
Scope of existing pricing initiative
The administration has already secured agreements with more than a dozen pharmaceutical companies to sell select drugs directly to consumers under the “Most Favored Nation” framework. The initiative aims to align U.S. drug prices more closely with lower prices available abroad.
However, the program currently covers only a limited number of medications. Many of those drugs have generic equivalents available at lower prices through existing market channels.
Under the draft order, the threat of high import tariffs could pressure additional manufacturers to participate in the program or shift operations domestically.
Economic and political implications
The potential tariffs come amid concerns within parts of the Republican Party that aggressive trade measures could contribute to higher consumer prices. Pharmaceutical imports play a critical role in U.S. supply chains, particularly for active ingredients used in domestic drug manufacturing.
Whether the proposed tariffs will advance in their current form remains uncertain. The White House has not publicly commented on the draft, and further revisions could emerge before any formal announcement.